Swiss regulator approves Pfizer/BioNTech booster for 16 and up
The extension of the Covid-19 booster only applies to the Pfizer/BioNtech vaccine.
Keystone / Christophe Archambault / Pool
Swissmedic has approved the extension of Covid-19 boosters for the Pfizer/BioNTech vaccine to all people aged 16 and over. This now "clears the way" for wider use of the booster vaccination, it said.
This content was published on
3 minutes
Keystone-SDA/jdp
Русский
ru
Вакцина от Pfizer/BioNTech одобрена для ревакцинации в Швейцарии
On Tuesday, the Swiss Agency for Therapeutic Products said that it was “adapting the product information” for the Pfizer/BioNTech so that a booster can be administered to people 16 years and up. In all cases, the third dose must be administered at least six months after the second dose.
Swissmedic reached the decision based on, among other things, a study involving 10,000 participants aged 16 to 87 years. The interim results of this study did not reveal any evidence of “new risk aspects” with the third vaccine dose, Swissmedic said.
Swissmedic “continues to monitor very closely the benefits and risks of the vaccine” for preventing Covid-19. The extension of boosters doesn’t apply to the Moderna vaccine.
The Federal Commission for Vaccination is now specifying detailed vaccination recommendations for the extension.
Booster doses of both the Pfizer/BioNTech and Moderna vaccines are currently being administered to specific groups, namely people over 65 and “people with a weakened immune system” from the age of 12. This followed Swissmedic’s approval of boosters at the end of October. A booster campaign for the rest of the population is expected to start soon.
More
More
Many cantons are unready for big Covid-19 booster campaign, says paper
This content was published on
The authorities are unprepared for a Covid-19 booster campaign for the under-65s, reports the SonntagsZeitung newspaper.
The Swiss government also announced on Tuesday that it has reserved around 8,000 packages of the antiviral drug Molnupiravir to treat Covid-19. A clinical trial has demonstrated efficacy in non-hospitalised Covid-19 patients at high risk of severe disease progression, said the Swiss National Scientific Taskforce.
With this deal, the government saidExternal link the country has access to another “promising” Covid-19 drug, in addition to casirivimab/imdevimab (developed by Roche and Regeneron) and sotrovimab (sold by GSK). In contrast to these monoclonal antibodies, molnupiravir is an antiviral treatment and can be administered orally. According to the Federal Office of Public Health, the government will cover the cost of treatment in the outpatient setting until it is reimbursed by mandatory health insurance.
Molnupiravir is expected to be available by January 2022 at the latest but it has not been approved in Switzerland. However, it can already be used to treat Covid-19 patients during the ongoing approval process after “an adaptation of Covid-19 Regulation 3, which has yet to take place,” the statement added.
The contract, the amount of which is confidential, was signed with the company MSD Merck Sharp & Dohme Switzerland.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Pilots’ union seeks to end deal with SWISS over working conditions
This content was published on
The Aeropers pilots’ union is expected to end its collective labour agreement with SWISS, as it pushes for better working conditions for its members.
Drugs often approved for wider use than tested, says Swiss study
This content was published on
A study by the University of Zurich, ETH Zurich and Yale and Harvard universities found that many medicines are approved for groups not tested in trials.
This content was published on
Over the four days, around 98,000 people – including volunteers – made their way up Bern’s local mountain for the 42nd edition of the festival.
Foreign residents in Moutier gain voting rights before town joins canton Jura
This content was published on
Foreign nationals living in Moutier will be able to vote in local and cantonal elections this year, even before the town joins the canton of Jura in 2026.
This content was published on
By 8am on Saturday, an 11-kilometre queue had formed at the Gotthard tunnel’s northern entrance, with drivers facing nearly two hours of delays.
Plant-based meat market in Switzerland set to grow to CHF361 million by 2030
This content was published on
Switzerland’s market for plant-based meat alternatives has a potential value of around CHF 242 million this year, though it remains a niche market.
This content was published on
The army is looking for a modern solution for its decommissioned fortress mortar bunkers, with plans to turn them into hardened defence hubs.
This content was published on
Spain ended Switzerland’s run in the Women’s Euros on Friday, but fans in Bern made history with the largest supporters’ march in Women’s Euros history.
This content was published on
Solar energy pioneer Raphaël Domjan and his team continued preparations for the altitude record attempt at 10,000 metres with the SolarStratos solar aircraft.
This content was published on
Cattle in the canton of Geneva and in the neighbouring region of Terre Sainte in the canton of Vaud are being vaccinated against the contagious viral skin nodule disease. The first cases of the animal disease were reported at the end of June in France, just outside Geneva.
This content was published on
Although it has only been in operation since 2000, the Institute of Research in Biomedicine (IRB) has already become a centre of international importance in the field of biomedical research. It has over 300 publications to its credit in academic journals, including Science and Nature. A visitor arriving at the institute for the first…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.